Formycon AG (0W4N.L)
EUR 53.2
(0.95%)
EUR 53.2
(0.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 23.3 Million EUR | 93.05% |
| 2022 | 12.07 Million EUR | 19.41% |
| 2021 | 10.11 Million EUR | 562.4% |
| 2020 | -2.18 Million EUR | -327.18% |
| 2019 | 962.44 Thousand EUR | -94.86% |
| 2018 | 18.72 Million EUR | 126.86% |
| 2017 | 8.25 Million EUR | 99.12% |
| 2016 | 4.14 Million EUR | -48.47% |
| 2015 | 8.04 Million EUR | 20.48% |
| 2014 | 6.67 Million EUR | 649.55% |
| 2013 | -1.21 Million EUR | -2357.4% |
| 2012 | 53.81 Thousand EUR | 258.29% |
| 2011 | -34 Thousand EUR | -179.98% |
| 2010 | 42.5 Thousand EUR | 1516.97% |
| 2009 | -3000.00 EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.9 Million EUR | 0.0% |
| 2023 Q4 | 5.66 Million EUR | 0.0% |
| 2023 FY | 23.3 Million EUR | 93.05% |
| 2023 Q2 | 17.63 Million EUR | 0.0% |
| 2022 Q2 | 5.32 Million EUR | 0.0% |
| 2022 FY | 12.07 Million EUR | 19.41% |
| 2022 Q4 | 6.74 Million EUR | 0.0% |
| 2021 Q2 | -8.13 Million EUR | 0.0% |
| 2021 FY | 10.11 Million EUR | 562.4% |
| 2021 Q4 | -4.79 Million EUR | 0.0% |
| 2020 Q4 | -2.57 Million EUR | 0.0% |
| 2020 Q2 | 390.7 Thousand EUR | 0.0% |
| 2020 FY | -2.18 Million EUR | -327.18% |
| 2019 FY | 962.44 Thousand EUR | -94.86% |
| 2019 Q4 | 294.22 Thousand EUR | 0.0% |
| 2019 Q2 | 668.21 Thousand EUR | 0.0% |
| 2018 FY | 18.72 Million EUR | 126.86% |
| 2018 Q4 | 5.33 Million EUR | 0.0% |
| 2018 Q2 | 13.38 Million EUR | 0.0% |
| 2017 Q4 | 6.3 Million EUR | 0.0% |
| 2017 FY | 8.25 Million EUR | 99.12% |
| 2017 Q2 | 1.95 Million EUR | 0.0% |
| 2016 Q2 | 2.91 Million EUR | 0.0% |
| 2016 Q4 | 1.22 Million EUR | 0.0% |
| 2016 FY | 4.14 Million EUR | -48.47% |
| 2015 FY | 8.04 Million EUR | 20.48% |
| 2015 Q4 | 2.5 Million EUR | 0.0% |
| 2015 Q2 | 5.53 Million EUR | 0.0% |
| 2014 Q4 | 1.09 Million EUR | 0.0% |
| 2014 FY | 6.67 Million EUR | 649.55% |
| 2014 Q2 | -4.33 Million EUR | 0.0% |
| 2013 Q3 | -303.71 Thousand EUR | -0.0% |
| 2013 Q1 | -303.71 Thousand EUR | -0.0% |
| 2013 Q2 | -303.71 Thousand EUR | 0.0% |
| 2013 Q4 | 1.66 Million EUR | 649.55% |
| 2013 FY | -1.21 Million EUR | -2357.4% |
| 2012 Q4 | -303.71 Thousand EUR | -2357.44% |
| 2012 Q3 | 13.45 Thousand EUR | 0.0% |
| 2012 Q2 | 13.45 Thousand EUR | 0.0% |
| 2012 Q1 | 13.45 Thousand EUR | 0.0% |
| 2012 FY | 53.81 Thousand EUR | 258.29% |
| 2011 Q4 | 13.45 Thousand EUR | 258.28% |
| 2011 Q3 | -8500.00 EUR | 0.0% |
| 2011 Q1 | -8500.00 EUR | 0.0% |
| 2011 Q2 | -8500.00 EUR | 0.0% |
| 2011 FY | -34 Thousand EUR | -179.98% |
| 2010 FY | 42.5 Thousand EUR | 1516.97% |
| 2010 Q4 | -8500.00 EUR | -179.98% |
| 2010 Q3 | 10.62 Thousand EUR | 0.0% |
| 2010 Q2 | 10.62 Thousand EUR | 0.0% |
| 2010 Q1 | 10.62 Thousand EUR | 0.0% |
| 2009 Q3 | -750.00 EUR | 0.0% |
| 2009 Q1 | -750.00 EUR | 0.0% |
| 2009 Q2 | -750.00 EUR | 0.0% |
| 2009 FY | -3000.00 EUR | 0.0% |
| 2009 Q4 | 10.62 Thousand EUR | 1516.93% |
| 2008 Q4 | -750.00 EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | 93.492% |
| Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 95.178% |
| Vetoquinol SA | 291.37 Million EUR | 92.002% |
| Valneva SE | 52.83 Million EUR | 55.893% |
| AB Science S.A. | 587 Thousand EUR | -3870.187% |
| Nanobiotix S.A. | 42.35 Million EUR | 44.981% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -1657.541% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 852.989% |
| BioSenic S.A. | 543 Thousand EUR | -4191.897% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -495.427% |